Safety assessments indicated that gastrointestinal adverse activities, largely nausea and diarrhea, were being dose-dependent but frequently gentle and transient. These conclusions set up the therapeutic window and educated dose variety for subsequent Section 3 trials.This scaled-down dimensions permits orforglipron to survive digestion and be abso